Does the media favor JNJ or EBS?

In the previous week, Johnson & Johnson had 64 more articles in the media than Emergent Biosolutions. MarketBeat recorded 70 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.91 beat Emergent Biosolutions' score of 0.26 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 41 Very Positive mention(s) 11 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Positive Emergent Biosolutions 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to EBS or AKTS?

In the previous week, Emergent Biosolutions had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for Emergent Biosolutions and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat Emergent Biosolutions' score of 0.26 indicating that Aktis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORIC or EBS?

In the previous week, Emergent Biosolutions had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Emergent Biosolutions and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Emergent Biosolutions' score of 0.26 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Emergent Biosolutions 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or EBS?

In the previous week, Emergent Biosolutions had 4 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Emergent Biosolutions and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.83 beat Emergent Biosolutions' score of 0.26 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer REPL or EBS?

In the previous week, Replimune Group had 10 more articles in the media than Emergent Biosolutions. MarketBeat recorded 16 mentions for Replimune Group and 6 mentions for Emergent Biosolutions. Replimune Group's average media sentiment score of 0.34 beat Emergent Biosolutions' score of 0.26 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Emergent Biosolutions (EBS) Competitors

$6.80 -0.22 (-3.08%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$6.83 +0.02 (+0.37%)

As of 09/18/2026 08:00 PM Eastern

Compare

EBS vs. JNJ, AKTS, ORIC, MGTX, and REPL

Should you buy Emergent Biosolutions stock or one of its competitors? Emergent Biosolutions's main competitors and comparable companies include Johnson & Johnson (JNJ), Aktis Oncology (AKTS), Oric Pharmaceuticals (ORIC), MeiraGTx (MGTX), and Replimune Group (REPL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Emergent Biosolutions compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Johnson & Johnson had 64 more articles in the media than Emergent Biosolutions. MarketBeat recorded 70 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 0.91 beat Emergent Biosolutions' score of 0.26 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	41 Very Positive mention(s)	11 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Positive
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.91	$26.80B	$8.63	31.28
Emergent Biosolutions	$742.90M	0.47	$52.60M	-$3.55	N/A

Johnson & Johnson has a net margin of 21.48% compared to Emergent Biosolutions' net margin of -22.95%. Johnson & Johnson's return on equity of 32.42% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Johnson & Johnson presently has a consensus target price of $274.13, suggesting a potential upside of 1.54%. Emergent Biosolutions has a consensus target price of $10.00, suggesting a potential upside of 46.97%. Given Emergent Biosolutions' higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Johnson & Johnson beats Emergent Biosolutions on 13 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Aktis Oncology?

Emergent Biosolutions (NYSE:EBS) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Emergent Biosolutions has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.47	$52.60M	-$3.55	N/A
Aktis Oncology	$6.50M	180.93	-$63.73M	-$0.82	N/A

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Emergent Biosolutions had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for Emergent Biosolutions and 2 mentions for Aktis Oncology. Aktis Oncology's average media sentiment score of 0.86 beat Emergent Biosolutions' score of 0.26 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Aktis Oncology	N/A	N/A	N/A

Emergent Biosolutions presently has a consensus target price of $10.00, indicating a potential upside of 46.97%. Aktis Oncology has a consensus target price of $35.63, indicating a potential upside of 62.82%. Given Aktis Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Aktis Oncology is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

Emergent Biosolutions and Aktis Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Emergent Biosolutions	-22.95%	16.35%	6.17%

Oric Pharmaceuticals presently has a consensus price target of $19.60, indicating a potential upside of 53.24%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 46.97%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oric Pharmaceuticals is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Oric Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Emergent Biosolutions has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

Emergent Biosolutions has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Emergent Biosolutions	$742.90M	0.47	$52.60M	-$3.55	N/A

In the previous week, Emergent Biosolutions had 3 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Emergent Biosolutions and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Emergent Biosolutions' score of 0.26 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Emergent Biosolutions beats Oric Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Emergent Biosolutions compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

MeiraGTx currently has a consensus price target of $26.17, indicating a potential upside of 97.48%. Emergent Biosolutions has a consensus price target of $10.00, indicating a potential upside of 46.97%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts clearly believe MeiraGTx is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

MeiraGTx has a net margin of 19.87% compared to Emergent Biosolutions' net margin of -22.95%. MeiraGTx's return on equity of 283.85% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Emergent Biosolutions	-22.95%	16.35%	6.17%

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Emergent Biosolutions has higher revenue and earnings than MeiraGTx. Emergent Biosolutions is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	15.63	-$114.20M	$0.71	18.66
Emergent Biosolutions	$742.90M	0.47	$52.60M	-$3.55	N/A

In the previous week, Emergent Biosolutions had 4 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Emergent Biosolutions and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.83 beat Emergent Biosolutions' score of 0.26 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

Summary

MeiraGTx beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.

How does Emergent Biosolutions compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Replimune Group presently has a consensus target price of $12.00, indicating a potential downside of 8.19%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 46.97%. Given Emergent Biosolutions' higher possible upside, analysts plainly believe Emergent Biosolutions is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Replimune Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

Replimune Group has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Emergent Biosolutions	-22.95%	16.35%	6.17%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Replimune Group had 10 more articles in the media than Emergent Biosolutions. MarketBeat recorded 16 mentions for Replimune Group and 6 mentions for Emergent Biosolutions. Replimune Group's average media sentiment score of 0.34 beat Emergent Biosolutions' score of 0.26 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Emergent Biosolutions has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Emergent Biosolutions	$742.90M	0.47	$52.60M	-$3.55	N/A

Summary

Replimune Group and Emergent Biosolutions tied by winning 8 of the 16 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EBS vs. The Competition

Export

Metric	Emergent Biosolutions	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$348.66M	$3.90B	$7.24B	$23.10B
Dividend Yield	N/A	3.64%	2.57%	3.62%
P/E Ratio	-1.92	14.23	275.49	28.21
Price / Sales	0.47	1,419.61	646.01	20.34
Price / Cash	1.86	108.90	76.25	36.36
Price / Book	0.68	15.45	10.46	4.67
Net Income	$52.60M	-$22.86M	$3.49B	$1.07B
7 Day Performance	8.74%	-1.21%	0.59%	-1.64%
1 Month Performance	40.00%	-3.29%	-1.74%	-3.60%
1 Year Performance	-17.43%	37.74%	18.13%	8.41%

Emergent Biosolutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EBS Emergent Biosolutions	4.3173 of 5 stars	$6.80 -3.1%	$10.00 +47.0%	-17.4%	$348.66M	$742.90M	N/A	900
JNJ Johnson & Johnson	4.3811 of 5 stars	$266.81 +0.5%	$274.13 +2.7%	+53.4%	$640.02B	$94.19B	30.92	138,200	Trending News Analyst Revision
AKTS Aktis Oncology	3.0417 of 5 stars	$23.17 -0.6%	$35.63 +53.8%	N/A	$1.25B	$10.06M	N/A	79
ORIC Oric Pharmaceuticals	2.3248 of 5 stars	$12.65 +5.1%	$19.60 +54.9%	+21.1%	$1.25B	N/A	N/A	111	Positive News
MGTX MeiraGTx	3.9097 of 5 stars	$12.88 +0.7%	$26.17 +103.2%	+75.3%	$1.23B	$81.39M	18.14	393	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EBS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, AKTS, ORIC, MGTX, and REPL

How does Emergent Biosolutions compare to Johnson & Johnson?

Summary

How does Emergent Biosolutions compare to Aktis Oncology?

Summary

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Summary

How does Emergent Biosolutions compare to MeiraGTx?

Summary

How does Emergent Biosolutions compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Emergent Biosolutions (EBS) Competitors

EBS vs. JNJ, AKTS, ORIC, MGTX, and REPL

How does Emergent Biosolutions compare to Johnson & Johnson?

Does the media favor JNJ or EBS?

Which has higher valuation & earnings, JNJ or EBS?

Is JNJ or EBS more profitable?

Which has more volatility & risk, JNJ or EBS?

Do insiders & institutionals have more ownership in JNJ or EBS?

Do analysts prefer JNJ or EBS?

Summary

How does Emergent Biosolutions compare to Aktis Oncology?

Which has better valuation & earnings, EBS or AKTS?

Do insiders and institutionals have more ownership in EBS or AKTS?

Does the media refer more to EBS or AKTS?

Is EBS or AKTS more profitable?

Do analysts prefer EBS or AKTS?

Summary

How does Emergent Biosolutions compare to Oric Pharmaceuticals?

Do insiders & institutionals hold more shares of ORIC or EBS?

Is ORIC or EBS more profitable?

Do analysts recommend ORIC or EBS?

Which has more risk & volatility, ORIC or EBS?

Which has better valuation and earnings, ORIC or EBS?

Does the media favor ORIC or EBS?

Summary

How does Emergent Biosolutions compare to MeiraGTx?

Do analysts rate MGTX or EBS?

Is MGTX or EBS more profitable?

Do institutionals and insiders believe in MGTX or EBS?

Which has stronger earnings & valuation, MGTX or EBS?

Does the media favor MGTX or EBS?

Which has more risk and volatility, MGTX or EBS?

Summary

How does Emergent Biosolutions compare to Replimune Group?

Do analysts prefer REPL or EBS?

Which has more risk & volatility, REPL or EBS?

Is REPL or EBS more profitable?

Do insiders and institutionals believe in REPL or EBS?

Does the media prefer REPL or EBS?

Which has preferable valuation & earnings, REPL or EBS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EBS vs. The Competition

Emergent Biosolutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools